BRPI0513467A - composições estáveis que contêm vesìculas de membrana externa, métodos de fabricação - Google Patents

composições estáveis que contêm vesìculas de membrana externa, métodos de fabricação

Info

Publication number
BRPI0513467A
BRPI0513467A BRPI0513467-6A BRPI0513467A BRPI0513467A BR PI0513467 A BRPI0513467 A BR PI0513467A BR PI0513467 A BRPI0513467 A BR PI0513467A BR PI0513467 A BRPI0513467 A BR PI0513467A
Authority
BR
Brazil
Prior art keywords
compositions containing
manufacturing methods
stable compositions
outer membrane
membrane vesicles
Prior art date
Application number
BRPI0513467-6A
Other languages
English (en)
Inventor
Andrew Gorringe
Phillip Vincent
Denise Halliwell
Karen Reddin
Original Assignee
Health Prot Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Prot Agency filed Critical Health Prot Agency
Publication of BRPI0513467A publication Critical patent/BRPI0513467A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Detergent Compositions (AREA)
  • Cosmetics (AREA)
  • Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)

Abstract

COMPOSIçõES ESTáVEIS QUE CONTêM VESìCULAS DE MEMBRANA EXTERNA, MéTODOS DE FABRICAçãO. Uma preparação de OMV que compreende OMVs que têm uma mudança de superfície suficientemente positiva ou negativa para substancialmente agregar.
BRPI0513467-6A 2004-07-19 2005-07-18 composições estáveis que contêm vesìculas de membrana externa, métodos de fabricação BRPI0513467A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0416120.4A GB0416120D0 (en) 2004-07-19 2004-07-19 Stable compositions containing OMV's
PCT/GB2005/002817 WO2006008504A1 (en) 2004-07-19 2005-07-18 Stable compositions containing outer membrane vesicles, methods of manufacturing

Publications (1)

Publication Number Publication Date
BRPI0513467A true BRPI0513467A (pt) 2008-05-06

Family

ID=32893812

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513467-6A BRPI0513467A (pt) 2004-07-19 2005-07-18 composições estáveis que contêm vesìculas de membrana externa, métodos de fabricação

Country Status (9)

Country Link
US (1) US7820185B2 (pt)
EP (1) EP1778182B1 (pt)
AT (1) ATE465713T1 (pt)
AU (1) AU2005263950B2 (pt)
BR (1) BRPI0513467A (pt)
CA (1) CA2574302A1 (pt)
DE (1) DE602005020942D1 (pt)
GB (1) GB0416120D0 (pt)
WO (1) WO2006008504A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2012001399A1 (es) 2009-12-03 2013-03-08 Novartis Ag Metodo para fabricar adyuvante para vacuna (emulsion aceite/agua con escualeno, polisorbato 80 y trioleato de sorbitan), que comprende (i) formar primera emulsion en homogenizador desde un contendor a otro para formar segunda emulsion, (ii) y microfluidizar primera emulsion para formar segunda emulsion.
CN104688687A (zh) * 2009-12-03 2015-06-10 诺华股份有限公司 疫苗佐剂制备中的亲水过滤
DE102009056871A1 (de) 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
DE102009056883B4 (de) 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
EP2506834B1 (en) 2009-12-03 2016-03-02 Novartis AG Circulation of components during homogenization and microfluidization of emulsions
JP2011163623A (ja) * 2010-02-08 2011-08-25 Osaka Gas Co Ltd スケール防止方法
GB201009676D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
EP3307890A1 (en) 2015-06-10 2018-04-18 Board of Regents, The University of Texas System Use of exosomes for the treatment of disease
CA3017586A1 (en) * 2016-03-15 2017-09-21 Codiak Biosciences, Inc. Therapeutic membrane vesicles
CA3062426A1 (en) 2017-05-08 2018-11-15 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
BR112023002872A2 (pt) 2020-08-20 2023-03-14 Inst Finlay De Vacunas Composição de vacina que induz uma resposta imune contra o vírus sars-cov-2, procedimento para obter as omvs, e, uso da composição de vacina

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2023448C1 (ru) 1987-07-30 1994-11-30 Сентро Насьональ Де Биопрепарадос Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в
NL9002092A (nl) 1990-09-25 1992-04-16 Nederlanden Staat Vaccin, geschikt voor de bestrijding van bordetella pertussis.
EP0624376B1 (en) 1993-05-13 2000-03-15 American Cyanamid Company Preparation and uses of LOS-depleted outer membrane proteins of gram-negative cocci
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
ES2260291T3 (es) * 2000-09-28 2006-11-01 Chiron Corporation Microparticulas para la administracion de acidos nucleicos heterologos.
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
EP1585504A4 (en) * 2002-11-06 2009-07-15 Azaya Therapeutics Inc Protein stabilized liposomal formulations of pharmaceutical active ingredients

Also Published As

Publication number Publication date
DE602005020942D1 (de) 2010-06-10
AU2005263950A1 (en) 2006-01-26
GB0416120D0 (en) 2004-08-18
ATE465713T1 (de) 2010-05-15
US7820185B2 (en) 2010-10-26
EP1778182B1 (en) 2010-04-28
AU2005263950B2 (en) 2010-02-04
CA2574302A1 (en) 2006-01-26
US20090041807A1 (en) 2009-02-12
WO2006008504A1 (en) 2006-01-26
EP1778182A1 (en) 2007-05-02

Similar Documents

Publication Publication Date Title
CY1124333T1 (el) Συνθεσεις ποτου
BRPI0520870B8 (pt) compostos intermediários para a preparação de alfa-mercaptoacetanilidas de s-triazolila
CL2012003656A1 (es) Uso de una composicion que comprende una enzima de reemplazo para la enzima lisosomal a una concentracion mayor a 5 mg/ml para tratar sintomas somaticos de la deficiencia de la enzima subyacente.
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
BRPI0513467A (pt) composições estáveis que contêm vesìculas de membrana externa, métodos de fabricação
BRPI0906197B8 (pt) forma de administração em formato de tira
CY1119041T1 (el) Αλκοολικες συνθεσεις που παρουσιαζουν ελαττωμενο κινδυνο ακεταλδεϋδαιμιας
HN2012001223A (es) Antagonistas de pcsk 9
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
MX393384B (es) Adyuvantes sinteticos de glucopiranosil-lipido.
WO2008149177A3 (en) Marine lipid compositions and uses thereof
NO20081034L (no) Pyrimidinforbindelser som serotoninreseptormodulatorer
DE112007001307A5 (de) Mikrobiologische Herstellung von 3-Hydroxyisobuttersäure
UY32292A (es) Agonistas de s1p1 y métodos de preparación y uso
CR9246A (es) Formulaciones terapeuticas del factor de crecimiento de queratinocitos
BRPI0511615A (pt) forma de administração oral compreendendo bactéria probiótica
AR072161A1 (es) Composicion con gradiente de grasas
MX373170B (es) Variantes de la familia il-1.
SV2011003827A (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
EA200900780A1 (ru) Аналоги эпотилона, модифицированные в положениях c12-c13, как противораковые лекарственные средства
CY1110891T1 (el) Παραγωγα 6-ετεροαρυλπυριδοϊνδολονης, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη αγωγη
CR9108A (es) Prevencion de infecciones endoparasitas verticales
CR11755A (es) Dronedarona para la prevencion de la cardioversion
TR201109686T2 (tr) Olmesartan'ın Farmasötik Bileşimleri.
CL2008002060A1 (es) Compuestos derivados de sulfonamida, inhibidores de la produccion de beta amiloide; metodo de preparacion; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento de enfermedades tales como alzheimer, angiopatia amiloide, sindrome de down, entre otras.

Legal Events

Date Code Title Description
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: ARQUIVAMENTO DEFINITIVO

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2300 DE 03/02/2015 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A, 8A, 9A, 10A, 11A, 12A, 13A, 14A E 15A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.